{"prompt": "['6.', 'STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN', 'The primary study analysis will take place when all study patients have completed their last', 'study treatment administration in the Treatment Cross-over Period. Summaries of secondary', 'study endpoints, including patient reported TASQ and EORTC QLQ-C30 responses,', 'selection of treatment administration method for the Treatment Continuation Period, HCP', 'reported HCPQ responses and safety endpoints will be included in the primary analysis.', 'An interim safety analysis that includes the study safety endpoints may be conducted. The', 'decision to conduct an interim safety analysis will be based on ongoing review of safety data', 'by the Medical Monitor.An interim analysis will be conducted to support a planned regulatory', 'filing for FDC (see Section 6.6).', 'The final study analysis that includes all secondary endpoints including safety and efficacy', 'endpoints will be conducted after the end of the study.', 'The Intent-to-Treat (ITT) population will include all patients randomized into the study,', 'allocated to their randomized treatment arm. Summaries of patient and HCP reported', 'outcomes and efficacy endpoints will be based on the ITT population.', 'The modified ITT (mlTT) population will include all patients who received at least one dose', 'of pertuzumab and trastuzumab FDC SC and one dose of P+H IV during the Treatment', 'Cross-over Period and subsequently answered at least Question 1 of the PPQ. A sensitivity', 'analysis of PROs, including the primary endpoint, and HCP reported outcomes will be based', 'on the mITT population.', 'The Safety population will include all patients who received at least one dose of any study', 'drug categorized according to the study drug administered. All safety analyses will be based', 'on the Safety population.', 'Continuous variables will be summarised by the mean, standard deviation, median and', 'range (minimum and maximum). Categorical variables will be summarised by number /', 'percentage of patients.', 'Further details about the planned analyses will be presented in the Statistical Analysis Plan.', '6.1', 'DETERMINATION OF SAMPLE SIZE', 'The primary study objective is to estimate the proportion of patients who express a', 'preference for pertuzumab and trastuzumab FDC SC.', 'The planned total sample size of 140 patients is based on an assumed rate of 70% of', 'patients preferring pertuzumab and trastuzumab FDC SC. To achieve a distance of', 'approximately', '8% from the estimated proportion to 95% CI limits, a total of 126 patients are needed for', 'the evaluation of preference. The final target sample size was increased to approximately', '140 patients to allow for 10% of the patients not providing an evaluable preference', 'assessment.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '81 / Protocol MO40628, Version 12']['6.2', 'SUMMARIES OF CONDUCT OF STUDY', 'Enrolment, eligibility violations and patient disposition will be summarized for patients by', \"treatment arm. Reasons for patient's study treatment discontinuation and patient's reasons\", 'for study discontinuation will be listed by patient and summarized. Major protocol deviations', 'will be listed and evaluated for their potential effects on the interpretation of study results.', 'Median follow-up on treatment and on study, estimated with corresponding 95% CI by the', 'reverse Kaplan-Meier approach, will be presented.', '6.3', 'SUMMARIES OF DEMOGRAPHIC AND BASELINE CHARACTERISTICS', 'Demographic variables and other baseline and disease characteristics will be summarized', 'overall, by treatment arm using descriptive statistics.', '6.4', 'PRIMARY ENDPOINT ANALYSIS', 'The primary objective of this study is to evaluate patient preference for pertuzumab and', 'trastuzumab FDC SC based on the proportion of patients indicating an overall preference for', 'pertuzumab and trastuzumab FDC SC in Question 1 of the PPQ. Question 1 of the PPQ is', 'as follows: \"All things considered, which method of administration did you prefer?\".', 'A point estimate with associated 95% CI for the proportion of patients who preferred', 'pertuzumab and trastuzumab FDC SC will be calculated for the mITT and ITT populations.', 'The primary endpoint will also be presented by neoadjuvant chemotherapy regimen', '(anthracyclines + taxanes / carboplatin + taxanes / taxanes only), neoadjuvant treatment', 'response (pCR/non-pCR) and hormone receptor status (positive / negative).', '6.5', 'SECONDARY ENDPOINT ANALYSES', 'Patient assessed satisfaction with pertuzumab and trastuzumab FDC SC and P+H IV will be', 'based on patient responses to Question 1 of the TASQ-SC and TASQ-IV respectively. In', 'addition, responses of the TASQ-SC and TASQ-IV will be summarized by domain (physical', 'impact, psychological impact, impact on activities of daily living, convenience and', 'satisfaction) over time.', 'The proportion of patients who select each treatment administration route for the Treatment', 'Continuation Period will be summarized for all patients who complete the Treatment Cross-', 'over Period.', 'EORTC QLQ-C30 scores including change from baseline, will be summarised by treatment', 'arm and by time.', 'Healthcare professional perception of time/resource use and convenience with pertuzumab', 'and', 'trastuzumab FDC SC will be assessed by summarizing responses to individual', 'questions of the HCPQs.', '6.5.1', 'Safety Analyses', 'Safety analyses will be conducted based on the Safety Population.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '82 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}